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Abstract
The aim. Estimation of ST2 plasma level in patients with acute myocardial infarction without ST elevation (NSTEMI) and its 
relationship with different clinical characteristics.
Materials and methods. 165 patients aged from 35 to 79 (average of 60.7±0.8 years) with various forms of coronary artery dis-
ease (CAD) with and without arterial hypertension were examined. The variability of plasma ST2 level in different forms of CAD and 
in NSTEMI group was analyzed depending on gender-age and clinical characteristics and features of the disease course.
Results:
The results of the present investigation were that the ST2 level in the main cohort was in range from 5.5 to 233.9 (in the mid-
dle – 49.8±3.5 ng/ml (median indicator – 34.7 and the interquartile range – 21.9 and 59.1 respectively). 
Significantly higher ST2 levels were found in patients with NSTEMI, unlike the comparison group, in the median analysis 
(35.9 vs. 27.7 ng/ml, p=0.047) and no statistical differences were observed in the mean values.
In patients with NSTEMI, a certain association of ST2 level in plasma with the MI course was detected. A higher level of neu-
rohormone is registered with anterior unlike posterior ECG localization of MI; at high unlike moderate risk on the GRACE scale; when 
complicated unlike the uncomplicated course of MI; in the case of acute HF and cardiac arrhythmias unlike patients with the absence 
of these manifestations in the acute period of MI. 
Conclusions. High variability of ST2 level in plasma was demonstrated in patients with NSTEMI on the first day after desta-
bilization (minimum and maximum values – 12.7 and 233.9 respectively, median – 35.9 and interquartile range – 25.9 and 55.7 ng/ml).
It is shown that significantly higher ST2 level in plasma is determined in patients with acute MI regardless of its variant among 
different clinical forms of CAD.
It is found that significantly higher level of ST2 in patients with NSTEMI is recorded in the case of concomitant HTN and 
type 2 diabetes, with smoking and heavy cardiovascular heredity. Proved influence of the character of MI course on the level of ST2 
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in plasma, significantly higher level of neurohormone was determined with anterior localization of MI, high risk on the GRACE scale 
(≥140 points), complicated course of MI, development of cardiac arrhythmias and HF in the acute period of MI.
Keywords: NSTEMI, biomarkers, ST2, GRACE scale.
DOI: 10.21303/2504-5679.2020.001098
1. Introduction
The analysis of the health dynamics status among Ukrainian population in recent years 
shows a negative trend, namely the deterioration of life quality and patients life expectancy [1, 2]. 
An indisputable leader in this process is coronary artery disease (CAD) and especially its acute 
forms, which are associated with high mortality [3, 4]. On this basis, the study of different aspects 
of this problem is of great interest for the practical health care of Ukraine.
Among the acute forms of CAD, NSTEMI is associated with extremely unanticipated 
course and unfavorable prognosis in the near and distant period [4]. Therefore, the development 
of NSTEMI stratification and prognosis is in the focus of scientific society. In this sense, vari-
ous non-invasive biomarkers, such as troponin I (TnI), natriuretic peptide (BNP and NT-proBNP), 
galectin-3, growth factor-expressing gene 2 (ST2) and others, have been recently studied in detail 
[5]. Among the latter, a great deal of attention is paid to ST2 [6].
ST2 as a neurohumoral factor attracted attention due to already available scientific data on 
its unique properties and a fairly wide range of pathophysiological effects and a potential role in 
the diagnosis and prognosis of asymptomatic and symptomatic structural remodelling and fibrosis 
of myocardium and myocardial dysfunction [7, 8]. The diagnostic value of the biomarker has been 
demonstrated in both acute coronary syndromes and chronic stable heart failure [9, 10]. ST2 has 
proven to be a highly informative marker in predicting left ventricular remodeling and monitoring 
positive treatment response in patients with systolic heart failure (HF), exceeding the sensitivity of 
factors such as NT-proBNP, highly sensitive cardiac troponin T and galectin-3 [11, 12].
Thus, the modern scientific sources analysis demonstrates the prospect of using ST2 level 
in plasma as a diagnostic marker that reflects the presence and severity of structural remodelling 
of myocardium in various cardiovascular pathologies, including MI [13, 14].
The aim of the study was to evaluate ST2 level in plasma among the patients with NSTEMI 
and its relationship according to different clinical characteristics.
2. Materials and methods
All studies conform to the principles of the Declaration of Helsinki of the World Med-
ical Association. The study protocol, the form of informed consent of patients and other doc-
uments related to the study were approved at the meeting of the Academic Council of the 
National Pirogov Memorial Medical University, Vinnytsya (excerpt from the protocol No. 2 
from 28.11.2017). Informed consent to participate in the study was discussed and signed by all 
study participants.
The study is based on the results of a comprehensive examination of 165 patients aged 35 
to 79 (average 60.7±0.8) years with various forms of CAD with and without arterial hypertension 
(HTN). Among the surveyed 114 (69.1 %) patients were male and 51 (30.9 %) were female respec-
tively. The ratio of men to women was 2.2 to 1.0, indicating a significant predominance in the study 
of male patients (p<0.0001).
At the time of their inclusion in the study, all patients were hospitalized in the cardiology 
department for infarction patients of the Vinnytsya Regional Clinical Medical Diagnostic Center 
for Cardiovascular Pathology for 2016–2018 years.
The criteria for patient inclusion in the study were: different forms of CAD (NSTEMI, 
STEMI, NSTE-ACS, chronic coronary syndromes) and patients age from 30 to 80 years. The ex-
clusion criteria were: 
1) past and repeated acute myocardial infarction; 
2) the age of patients under 30 and over 80; 
3) HF NYHA III–IV at the time of the study inclusion; 
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4) diseases of the respiratory system, kidneys and liver, which were accompanied by signs 
of pulmonary, renal and hepatic failure; anemic conditions with haemoglobin levels below 110 g/l; 
5) presence of rheumatic and congenital heart defects, idiopathic and inflammatory myo-
cardial lesions; 
6) malignancies, severe neuropsychiatric disorders, alcohol abuse.
The main clinical trial was presented to 90 patients with NSTEMI aged 38 to 79 (mean 
61.3±1.1) years. Among them, 60 (66.7 %) patients were male and 30 (33.3 %) were female respec-
tively. The ratio of men to women was 2.0 to 1.0 (p<0.0001). It was noted that in the main clinical 
group, as well as in the general cohort of patients, men predominated significantly. Time from 
the moment of destabilization to hospitalization in the hospital ranged from 1 to 24 and averaged 
10.6±1.0 hours. In the vast majority (87.8 %) of patients with NSTEMI according to the ECG re-
corded anterior localization of MI (in 87.8 % – depression of ST-segment from 2 to 5 mm and in 
12.2 % – T-wave inversion from 2 to 6 mm in two or more leads) and an increase in plasma troponin 
levels compared to the reference rate of 2.5 to 18.4 ng/ml (7.5±0.5 ng/ml on average).
As groups of comparison were formed 3 groups with other different clinical forms of CAD. 
Thus, group 1 consisted of 25 patients with verified chronic coronary syndromes (CCS) (mean 
age – 60.6±2.4 years, men – 68.0 % and women – 32.0 % respectively); group 2 – 25 patients with 
NSTE-ACS (mean age – 61.4±2.4 years, males – 68.0 % and females – 32.0 %, respectively) and 
3rd – 25 patients with STEMI (mean age 58.3±2.3 years, males 80.0 % and females 20.0 %, re-
spectively). In patients with STEMI, unlike the main group, there was a significantly shorter mean 
period from the destabilization onset to hospitalization (6.3 vs. 10.6 h, p<0.001) and the incidence 
of anterior MI localization (64.9 % vs. 87.8 %, p=0.006) and a higher mean troponin level (10.4 vs. 
7.5 ng/ml, p=0.003) which was logical.
The majority of the surveyed had concomitant HTN, the incidence of which was 84.4 % 
(n=76) in the main group and 85.3 % (n=64) in the comparison groups. Most patients had observed 
Crade II (32.9 % and 46.1 %, n=30 and 36) and Crade III of HTN (40.6 % and 35.9 %, n=37 and 
27 respectively). Such risk factor as smoking was determined in almost half of the surveyed – in 
45.6 % (n=41) of patients in the primary and in 58.7 % (n=44) – comparison groups respectively. In 
almost one third of patients, abdominal obesity of Grade I-II (BMI > 30 kg / m2) was determined 
in 32.2 % (n=29) of the primary and 42.7 % (n=32) of the comparison groups respectively. 11.1 % 
(n=10) and 14.7 % (n=11) of patients were diagnosed with type 2 diabetes mellitus and 50.0 % 
(n=45) and 42.7 % (n=32), respectively with impaired heredity in cardiovascular disease. 
Laboratory study of the plasma ST2 levels was performed by enzyme-linked immunosor-
bent assay in all patients on the first day of hospitalization before hospital coronary and ventricu-
lography (CVG). Presage® ST2 Assay EIA Test Kits No. BC-1065E and BC-1066E manufactured 
by CRITICAL DIAGNOSTICS 3030 Bunker Hill St. Suite 117A San Diego, CA 92109 were used 
to determine ST2.
The difference between the main clinical group and the comparison group, the gender dif-
ference and the difference of ST2 level depending on different clinical characteristics were calcu-
lated using nonparametric statistical methods (Mann-Whitney test). The statistical significance of 
the difference between the measured parameters among the CAD groups was calculated by Krus-
kal-Wallis ANOVA & Median test. 
3. Results 
The results of the present investigation were that the ST2 level in the main cohort was in 
range from 5.5 to 233.9 (in the middle – 49.8±3.5 ng/ml (median indicator – 34.7 and the inter-quar-
tile range – 21.9 and 59.1 respectively). Tables 1-2 show indicators of statistics, which characterize 
the variability of ST2 level in small groups of illnesses.
Noteworthy significantly higher ST2 level in patients with NSTEMI, unlike the comparison 
group, in the analysis of medians (35.9 vs. 27.7 ng/ml, p=0.047) and no statistical differences in the 
mean values. The latter index clearly argues, in the case of high variability of indicators in groups, 
the need to use nonparametric methods of comparison (the table compares the median of the indi-
cator according to Mann-Whitney U test).
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ST2 variation in plasma in the main clinical and comparison groups 
Groups Patients number
Variational statistics indicators
Min–Max (ng/ml) Mean±Standard error (ng/ml)
Median 
(25 and 75 Percentile) (ng/ml)
Patients with NSTEMI 90 12.7–233.9 50.3±4.5 35.9 (25.9; 55.7)
Patients with other forms of 
СAD
75 5.5–200.4 46.2±5.3 27.7 (18.4; 68.9)
Mann-Whitney U test: р=0.047
Note: NSTEMI – non-ST elevation myocardial infarction
Table 2
ST2 variations in patients with various forms of CAD 
Groups Patients number
Variational statistics indicators
Min–Max (ng/ml) Mean±Standard error (ng/ml)
Median 
(25 and 75 Percentile) 
(ng/ml)
1. NSTEMI 90 12.7–233.9 50.3±4.5 35.9 (25.9; 55.7)
2. NSTE-ACS 25 10.9–180.2 41.4±8.9 24.1 (17.1; 31.2)
3. STEMI 25 12.5–200.4 56.3±10.1 36.1 (21.6; 77.3)
4. CCS 25 5.5–158.4 39.8±8.8 23.4 (15.1; 48.9)
Intergroup analysis of ST2 level by Kruskal-Wallis ANOVA & Median test
Group 1 2 3 4
1 0.02 1.00 0.01
2 0.02 0.04 0.73
3 1.00 0.04 0.03
4 0.01 0.73 0.03
In turn, the comparison of ST2 levels in patients with various forms of CAD (Table 2) 
showed significant differences between groups with acute MI (1 and 3 groups) and patients with 
NSTE-ACS and CCS (2 and 4 groups) – 35.9 and 36.1 against 24.1 and 23.4 ng/ml, p<0.05 in the 
absence of significant differences between patients with different types of MI (35.9 and 36.1 ng/ml, 
p=1.00). Therefore, it should be thought that a significantly higher level of ST2 is present in patients 
with acute MI, regardless of its variant compared with patients with CCS and NSTE-ACS. 
The results of ST2 analysis in the main clinical group in gender and age (Table 3) did not 
show significant differences in biomarker’s levels in women and men (p=0.38), as well as patients 
of different age criteria (p=0.94).
Table 3
Plasma ST2 levels in patients with NSTEMI by sex and age 
Group Patients number Mean±Standard error  (ng/ml)
Median 
(25 and 75 Percentile) (ng/ml)
Male 60 50.1±5.0 36.9 (28.6; 56.6)
Female 30 50.7±9.3 34.1 (22.2; 53.9)
Mann-Whitney U test: р=0,38
up to 60 years 39 56.1±8.9 35.4 (25.9; 59.1)
60 years and older 51 46.1±4.5 36.9 (27.4; 55.3)
Mann-Whitney U test: р=0,94
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ST2 level analysis in plasma depending on different clinical characteristics (Table 4) 
showed significant higher hormone levels in patients with concomitant HTN (39.9 vs. 31.2 ng/ml, 
p=0.04) and type 2 diabetes (68.5 vs. 35.5 ng/ml, p=0.04), in the presence of such a risk factor as 
smoking (39.6 vs. 32.7 ng/ml, p=0.03) and impaired cardiovascular heredity (41.8 vs. 32.6 ng/ml, 
p=0.01). Therefore, based on the data obtained, it should be noted that in patients with NSTEMI, 
the ST2 level in plasma, in a certain way, depends on the presence of concomitant diseases such 
as HTN and type 2 diabetes, risk factors such as smoking and impaired hereditary cardiovascu-
lar pathology. The highest ST2 level was observed in patients with concomitant type 2 diabetes 
mellitus (68.5 ng/ml). The latter confirms the already known fact that type 2 diabetes is consid-
ered to be the most powerful factor in the development of myocardial dysfunction and HF in pa- 
tients with MI.
Table 4
Plasma ST2 levels in patients with NSTEMI depending on different clinical characteristics 
Group Patients number Mean±Standard error  (ng/ml)
Median 
(25 and 75 Percentile) (ng/ml)
MI 52 55.8±7.2 36.7 (28.2; 57.9)
Absent 38 43.2±4.5 35.0 (25.9; 52.1)
Mann-Whitney U test: р=0.47
Concomitant HTN 76 50.8±5.2 39.9 (25.9; 56.1)
Absent 14 47.7±8.4 31.2 (20.8; 41.4)
Mann-Whitney U test: р=0.04
Smoking 41 53.2±6.1 39.6 (28.6; 59.1)
Absent 49 48.1±6.6 32.7 (23.6; 50.8)
Mann-Whitney U test: р=0.03
Burdened heredity in cardio-
vascular morbidity
45 60.6±7.6 41.8 (30.6; 73.3)
Absent 45 40.5±4.8 32.6 (22.4; 46.1)
Mann-Whitney U test: р=0.01
Abdominal obesity 
(BMI> 30 kg/m2) 29 46.3±8.3 34.6 (28.6; 41.8)
Absent 61 52.3±5.5 37.1 (25.9; 59.1)
Mann-Whitney U test: р=0.29
Diabetes 10 85.3±23.0 68.5 (28.2; 100.5)
Absent 80 45.9±4.0 35.5 (25.9; 52.1)
Mann-Whitney U test: р=0.003
In turn, analysis of ST2 level depending on MI nature (Table 5) showed that a signifi-
cantly higher level of neurohormone was determined at anterior localization of MI according to 
the ECG (37.9 vs. 29.4 ng/ml, p=0.03), in the case of high risk on the GRACE scale (≥140 points) 
(42.0 vs. 30.3 ng/ml, p=0.01) and complicated course of MI (40.7 vs. 31.9 ng/ml, p=0.03). The 
complicated course of NSTEMI was registered by us in 22 (24.4 %) patients. Of these, 15 (16.7 %) 
observed acute cardiac arrhythmias, 3 (3.3 %) had cardiac conduction abnormalities, and 4 (4.4 %) 
had acute HF, which was consistent with Killip III. Of the acute cardiac arrhythmias, almost half 
(53.3 %, n=48) of patients reported frequent ventricular extrasystole with episodes of unstable ven-
tricular tachycardia, 20.0 % (n=18) had attacks of persistent ventricular monomorphic tachycardia 
and 26.7 % (n=24) had paroxysmal atrial fibrillation. From 3 (3.3 %) of patients with acute conduc-
tivity disorders, in 2 (66.7 %) cases reported intermittent atrio-ventricular block of II-III degree and 
in 1 case (33.3 %) – sino-atrial block of II degree.
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ST2 levels in patients with NSTEMI depending on MI course 
MI course characteristics Patients number Mean±Standard error (ng/ml) Median (25 and 75 Percentile) (ng/ml)
Frontal localization of MI 79 53.5±5.4 37.9 (29.6; 58.9)
Rear localization of MI 11 38.1±5.0 29.4 (23.2; 47.9)
Mann-Whitney U test: р=0,03
High risk (≥140 points) by 
Grace 36 46.1±5.7 42.0 (30.8; 64.1)
Low and moderate 
 (<140 points) by Grace
54 33.3±6.7 30.3 (21.8; 55.2)
Mann-Whitney U test: р=0,01
Uncomplicated course 68 42.8±5.5 31.9 (25.2; 46.4)
Complicated course 22 49.2±8.0 40.7 (32.9; 61.5)
Mann-Whitney U test: р=0,03
Acute heart rate disorders 15 62.7±15.1 47.1 (31.2; 87.5)
Absent 75 47.8±4.5 35.6 (25.7; 55.3)
Mann-Whitney U test: р=0,004
Conduction abnormalities 3 72.3±28.3 43.7 (38.2; 57.9)
Absent 87 49.0±4.5 35.2 (25.7; 55.3)
Mann-Whitney U test: р=0,13
Acute HF (Killip III) 4 57.0±7.4 56.3 (35.4; 103.9)
Absent 86 40.7±5.0 35.2 (25.9; 56.1)
Mann-Whitney U test: р=0,02
In addition, the analysis showed a significantly higher ST2 level in patients with NSTEMI 
in the presence of acute cardiac arrhythmias (47.1 vs 35.6 ng/ml, p=0.004) and acute HF (Killip III) 
(56.3 vs 35,2 ng/ml, p=0.02) during hospitalization of patients.
Thus, in patients with NSTEMI, a certain association of ST2 level in plasma with the MI 
course was detected. A higher level of neurohormone is registered with anterior unlike posterior 
ECG localization of MI; at high unlike moderate risk on the GRACE scale; when complicated 
unlike the uncomplicated course of MI; in the case of acute HF and cardiac arrhythmias unlike 
patients with the absence of these manifestations in the acute period of MI.
4. Discussion
The results obtained in the course of our study indicated a correlation of ST2 level with 
different clinical and instrumental characteristics. Thus, an increased level of biomarker was deter-
mined in patients with myocardial infarction compared with the control group, which is confirmed 
by the literature [15, 16]. The rate was higher in the group of patients with concomitant hyperten-
sion, hereditary history, smoking, diabetes and obesity. Most of the literature is centred around 
STEMI, while ST2 is not well understood in NSTEMI [9, 17]. 
We investigated ST2 levels depending on the localization of myocardial infarction and its 
complications, which obtained conclusive data regarding the increase of the level of biomarker in 
the main group compared with the control group.
Given that ST2 levels are correlated with the risk of an unfavourable course of myo-
cardial infarction, its determination in the early stages of the disease allows for appropriate 
correction of treatment, such as dose modification of drugs or changes in their combinations. 
If relevant clinical data are available with regard to STEMI, there is very little data regarding 
NSTEMI [18].
Study limitations. This study examines the therapeutic aspects of the ratio of ST2 
levels and the clinical-instrumental characteristics of NSTEMI, while the surgical aspects are 
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forced to be neglected. However, the data obtained during the study confirm the indisputable 
relationship between the level of biomarker and the character of the course of CAD and con-
comitant HF [19, 20].
Prospects for further research. Of great interest are the associations of ST2 level with 
the character of the anatomic lesions of the coronary arteries, in particular, the correlative con-
nections according to the SYNTAX score, but we attribute this research to further and pro-
spective studies. The following data will help to optimize the tactics of treating patients in the 
early period of myocardial infarction immediately after emergency coronary angiography and 
angioplasty.
5. Conclusions
1. High variability of ST2 level in plasma was demonstrated in patients with NSTEMI on 
the first day after destabilization (minimum and maximum values – 12.7 and 233.9 respectively, 
median – 35.9 and interquartile range – 25.9 and 55.7 ng/ml).
2. It is shown that significantly higher ST2 level in plasma is determined in patients with 
acute MI regardless of its variant among different clinical forms of CAD.
3. It is found that significantly higher level of ST2 in patients with NSTEMI is recorded in 
the case of concomitant HTN and type 2 diabetes, with smoking and heavy cardiovascular heredity. 
Proved influence of the character of MI course on the level of ST2 in plasma, significantly higher 
level of neurohormone was determined with anterior localization of MI, high risk on the GRACE 
scale (≥ 140 points), complicated course of MI, development of cardiac arrhythmias and HF in the 
acute period of MI.
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